For patients with platinum-refractory, recurrent or metastatic, PD-L1-negative HNSCC, an ongoing phase II/III study includes tremelimumab and durvalumab (anti-PD-L1) as separate monotherapies or in combination (NCT02319044). The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.